These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 9561922

  • 1. Control of IgE responses. V. Oral administration of a synthetic derivative of the inner bacterial cell wall (SDZ 280.636) to sensitized mice induces isotype specific suppression of peak hapten specific IgE antibody forming cell responses, serum IgE levels and immediate hypersensitivity responses.
    Auci DL, Kleiner GI, Chice SM, Athanassiades TJ, Dukor P, Durkin HG.
    Immunol Invest; 1998; 27(1-2):105-20. PubMed ID: 9561922
    [Abstract] [Full Text] [Related]

  • 2. Control of IgE responses. 4. Isotype-specific suppression of peak BPO-specific IgE antibody-forming cell responses and of BPO-specific IgE in serum by muramyldipeptide or murabutide after administration to mice by gavage.
    Auci DL, Carucci JA, Chice SM, Smith MC, Dukor P, Durkin HG.
    Int Arch Allergy Immunol; 1993; 101(2):167-76. PubMed ID: 8508053
    [Abstract] [Full Text] [Related]

  • 3. IL-6 mediated isotype specific suppression of hapten specific IgE in serum of BPO-KLH sensitized mice: role of IFN alpha in maintainance of hapten specific IgE responses.
    Auci DL, Miller H, Chice SM, Durkin HG.
    Immunol Invest; 1994 Apr; 23(3):213-21. PubMed ID: 8070849
    [Abstract] [Full Text] [Related]

  • 4. Control of IgE responses. II. Isotype specific suppression of peak hapten specific IgE antibody forming cell responses in BPO-KLH sensitized mice after oral administration of muramyldipeptide or murabutide.
    Auci DL, Chice SM, Dukor P, Durkin HG.
    Immunopharmacology; 1993 Apr; 26(2):157-69. PubMed ID: 8282540
    [Abstract] [Full Text] [Related]

  • 5. Cytokine-induced suppression and potentiation of hapten-specific immediate hypersensitivity responses.
    Auci DL, Kleiner G, Sheikh A, Acosta E, Athanassiadies TJ, Murali MR, Durkin HG.
    Immunol Invest; 1993 Apr; 22(3):205-18. PubMed ID: 7685321
    [Abstract] [Full Text] [Related]

  • 6. Control of IgE responses. III. IL-6 and IFN-alpha are isotype-specific regulators of peak BPO-specific IgE antibody-forming cell responses in mice.
    Auci DL, Kleiner GI, Chice SM, Dukor P, Durkin HG.
    Clin Immunol Immunopathol; 1993 Mar; 66(3):219-24. PubMed ID: 8432046
    [Abstract] [Full Text] [Related]

  • 7. Neuropeptide-mediated regulation of hapten-specific IgE responses in mice. II. Mechanisms of substance P-mediated isotype-specific suppression of BPO-specific IgE antibody-forming cell responses induced in vitro.
    Carucci JA, Herrick CA, Durkin HG.
    J Neuroimmunol; 1994 Jan; 49(1-2):89-95. PubMed ID: 7507499
    [Abstract] [Full Text] [Related]

  • 8. An in vitro murine model of a penicillin specific IgE anamnestic response.
    Smith MC, Heusser C, Wagner K, Blaser K, Durkin HG.
    J Immunol Methods; 1990 Jul 20; 131(1):55-64. PubMed ID: 2380568
    [Abstract] [Full Text] [Related]

  • 9. Regulation of hapten-specific memory IgE responses induced in vitro. Requirement for both Thy-1+ AsGM1+ and Thy-1+ AsGM1- cells and for IFN-alpha and IL-4.
    Herrick CA, Carucci JA, Kleiner GI, Durkin HG.
    J Immunol; 1993 Oct 01; 151(7):3440-9. PubMed ID: 8104220
    [Abstract] [Full Text] [Related]

  • 10. Peyer's patches and mesenteric lymph nodes are the sites of first appearance of IgE bearing B lymphocytes and hapten specific IgE antibody forming cells in BPO-KLH sensitized mice.
    Auci DL, Chice SM, Heusser C, Athanassiades TJ, Durkin HG.
    Reg Immunol; 1992 Oct 01; 4(4):216-24. PubMed ID: 1476874
    [Abstract] [Full Text] [Related]

  • 11. Neuropeptide-mediated regulation of hapten-specific IgE responses in mice. I. Substance P-mediated isotype-specific suppression of BPO-specific IgE antibody-forming cell responses induced in vivo and in vitro.
    Carucci JA, Auci DL, Herrick CA, Durkin HG.
    J Leukoc Biol; 1995 Jan 01; 57(1):110-5. PubMed ID: 7530276
    [Abstract] [Full Text] [Related]

  • 12. Tetracycline-mediated IgE isotype-specific suppression of ongoing human and murine IgE responses in vivo and murine memory IgE responses induced in vitro.
    Joks R, Smith-Norowitz T, Nowakowski M, Bluth MH, Durkin HG.
    Int Immunol; 2010 Apr 01; 22(4):281-8. PubMed ID: 20181654
    [Abstract] [Full Text] [Related]

  • 13. Suppression of in vivo IgE and tissue IL-4 mRNA induction by SDZ 280.636, a synthetic muramyl dipeptide derivative.
    Kricek F, Zunic M, Ruf C, De Jong G, Dukor P, Bahr GM.
    Immunopharmacology; 1997 Apr 01; 36(1):27-39. PubMed ID: 9129994
    [Abstract] [Full Text] [Related]

  • 14. Origin and fate of IgE-bearing lymphocytes. II. Gut-associated lymphoid tissue as sites of first appearance of IgE-bearing B lymphocytes and hapten-specific IgE antibody-forming cells in mice immunized with benzylpenicilloyl-keyhole limpet hemocyanin by various routes: relation to asialo GM1 ganglioside+ cells and IgE/CD23 immune complexes.
    Auci DL, Chice SM, Heusser C, Athanassiades TJ, Durkin HG.
    J Immunol; 1992 Oct 01; 149(7):2241-8. PubMed ID: 1388186
    [Abstract] [Full Text] [Related]

  • 15. IFN-alpha-mediated suppression of low-affinity FC(epsilon) receptors on Peyer's patch lymphocytes and augmentation of soluble CD23: implications for IgE responses.
    Miller H, Bluth MH, Chice SM, Durkin HG, Auci DL.
    J Leukoc Biol; 1996 May 01; 59(5):725-7. PubMed ID: 8656058
    [Abstract] [Full Text] [Related]

  • 16. Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs.
    Joks R, Durkin HG.
    Pharmacol Res; 2011 Dec 01; 64(6):602-9. PubMed ID: 21501686
    [Abstract] [Full Text] [Related]

  • 17. IgE-isotype-specific suppressor cells in the mouse: characterization using tetraparental chimera mice of high (DBA/2) and low (SJL) IgE responder embryos.
    Okudaira H, Terada E, Yokoyama M, Miyamoto T.
    Int Arch Allergy Appl Immunol; 1988 Dec 01; 85(4):462-6. PubMed ID: 2965683
    [Abstract] [Full Text] [Related]

  • 18. A 3 beta-cholestanyl-containing mono-benzylpenicilloyl oligoamide and peptide suppress anti-benzylpenicilloyl antibody formation in mice.
    Lüscher IF, De Weck A, Gitler C.
    Eur J Immunol; 1985 Mar 01; 15(3):243-50. PubMed ID: 3979422
    [Abstract] [Full Text] [Related]

  • 19. The introduction of one or two 3 beta-cholestanyl residues into benzylpenicilloyl-eicosa-L-lysines greatly potentiates their tolerogenicity for anti-benzylpenicillol IgE antibody formation.
    Lüscher IF, Weber E, de Weck AL.
    Eur J Immunol; 1984 Jan 01; 14(1):68-74. PubMed ID: 6229410
    [Abstract] [Full Text] [Related]

  • 20. Mouse anti-benzylpenicilloyl IgE monoclonal antibody: preparation, characterization and cross-reactivity.
    Fukushima H, Misaki R, Takeuchi M, Niinomi Y, Harada M.
    Clin Exp Immunol; 1987 May 01; 68(2):427-36. PubMed ID: 3652521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.